Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Do tiny cancer cells in lymph nodes matter? new study aims to find out

NCT ID NCT06689956

Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is for people with a low-risk type of uterine cancer (endometrial cancer). Researchers want to see if finding very small groups of cancer cells (called isolated tumor cells) in the first lymph nodes near the tumor changes the chance of the cancer coming back. About 212 participants will be followed over time, but no new treatment is given—this is just observation to learn more.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better predict recurrence risk in low-risk endometrial cancer, potentially guiding future treatment decisions.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to any change in care, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 212 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients diagnosed with low-risk endometrial cancer.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Low-risk endometrial cancer, defined as endometrioid, grade 1 or 2, International Federation of Gynecology and Obstetrics (FIGO) 2009 stage IA (FIGO 2023 stages IA1 and IA2), without substantial/extensive LVSI (≥ 5 vessels involved) at final pathology. Patients with focal LVSI (\< 5 vessels involved) will be included. * Complete surgical staging, including pelvic sentinel lymph node (SLN) biopsy per National Comprehensive Cancer Network (NCCN) guidelines and ultrastaging. * Extent of disease in SLN: ITC (defined as tumor cell aggregates ≤ 0.2 mm or \< 200 cells) * No adjuvant treatment after surgery * Research consent provided. Exclusion Criteria: * Prior neoadjuvant chemotherapy. * Planning to receive adjuvant treatment. * Presence of synchronous cancer (excluding non-melanoma skin cancer). * Extent of disease in SLN: micrometastasis (\> 0.2 to ≤ 2.0 mm) or macrometastasis (\> 2.0 mm). * Presence of substantial/extensive LVSI (≥ 5 vessels involved) at final pathology. * Prior invasive cancer diagnosis within 5 years of study entry (excluding non-melanoma skin cancer).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Figo grade 1 endometrial endometrioid adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endometrial carcinoma endometrial endometrioid adenocarcinoma stage I endometrioid carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Figo grade 1 endometrial endometrioid adenocarcinoma Figo grade 2 endometrial endometrioid adenocarcinoma Stage IA1 endometrial cancer figo 2023 Stage IA2 endometrial cancer figo 2023

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    20 sites in 10 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • AC Camargo Cancer Center

    RECRUITING

    São Paulo, Brazil

  • European Institute of Oncology

    RECRUITING

    Milan, MI, 20141, Italy

  • Fondazione IRCCS Istituto Nazionale Tumori

    RECRUITING

    Milan, MI, 20133, Italy

  • Hopital Maisonneuve Rosemont

    RECRUITING

    Montreal, Quebec, H1T 2M4, Canada

  • Hospital Materno Infantil Las Palmas

    RECRUITING

    Las Palmas, 35016, Spain

  • Hospital Universitario La Paz

    RECRUITING

    Madrid, 28029, Spain

  • Houston Methodist Hospital

    RECRUITING

    Houston, Texas, 77030, United States

  • IRCCS Fondazione San Gerardo dei Tintori

    NOT_YET_RECRUITING

    Monza, MB, 20900, Italy

  • Institut Universitaire du Cancer Toulouse Oncopole

    NOT_YET_RECRUITING

    Toulouse, 31100, France

  • Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale

    NOT_YET_RECRUITING

    Naples, 80131, Italy

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Email: •••••@•••••

  • Medical University of Vienna

    RECRUITING

    Vienna, Austria

  • Meir Medical Center, Faculty of Medicine - Tel-Aviv University

    NOT_YET_RECRUITING

    Kefar Sava, Israel

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

  • Ospedale Michele e Pietro Ferrero

    NOT_YET_RECRUITING

    Verduno, CN, 12060, Italy

  • Ospedale Regionale di Lugano, Civico

    RECRUITING

    Lugano, 6900, Switzerland

  • Policlinico Universitario Fondazione Agostino Gemelli

    RECRUITING

    Roma, RM, 00168, Italy

  • Sunnybrook Health Sciences, University of Toronto

    RECRUITING

    Toronto, Ontario, M4N 3M5, Canada

  • University Hospital Essen

    NOT_YET_RECRUITING

    Essen, 45147, Germany

  • University of Udine

    NOT_YET_RECRUITING

    Udine, UD, 33100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.